Answers are grounded in this paper and cite their sources.
Liraglutide, a glucagon‐like peptide‐1 receptor agonist, is widely used as a therapeutic macromolecule for the treatment of type 2 diabetes; however, its large‐scale production is limited by high manufacturing costs and the frequent occurrence of closely related deletion impurities during synthesis. In the present study, we describe a novel, impurity‐controlled, and industrially feasible synthetic strategy for liraglutide and its sequence‐modified analogs. This method utilizes solution‐phase incorporation of Pal‐γ‐Glu‐OtBu in combination with a preassembled Boc‐His (Boc)‐Ala‐Glu (OtBu)‐OH tripeptide fragment, effectively minimizing the formation of des‐His, des‐Ala, and des‐Glu impurities. The optimized protocol enabled the production of liraglutide and its analogs with consistent isolated yields and high chromatographic purity (> 95% by RP‐HPLC), suitable for subsequent biological evaluation. The antidiabetic potential of liraglutide and three sequence‐modified analogs, Lira (Trp‐O 25 ), Lira (desGly 31 ), and Lira (Glu 17 ), was evaluated using a Drosophila melanogaster model of high‐sucrose diet induced diabetes. Among these, Lira (Glu 17 ) exhibited the most pronounced metabolic improvements, significantly reducing free glucose ( p < 0.001), trehalose ( p < 0.001), and triglyceride levels ( p < 0.001) when compared to diabetic controls. Furthermore, this analog effectively decreased lipid accumulation and reactive oxygen species in larval gut tissues and enhanced locomotor performance in both larva and adult flies. While Lira (Trp‐O 25 ) also demonstrated beneficial effects, Lira (desGly 31 ) showed comparatively limited efficacy. Collectively, this study presents a cost‐effective and impurity‐controlled synthetic platform for liraglutide production and identifies Lira (Glu 17 ) as a promising analog with enhanced antidiabetic activity, offering valuable insights for peptide manufacturing and GLP‐1‐based therapeutic development.
No takes yet. Share an insight, caveat, or question.
Ravi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: